Aclaris Reports Third-Quarter 2026 Results, Updates on Clinical Program
Aclaris expects to initiate a Phase 2b trial of modzatinib (ATI-2138) in lichen planus in the fourth quarter.
Related stories
Western Union Terminates Agreement to Acquire Intermex
M impact | EQUITY | Nov 11, 2026, 04:45 AM UTC
Nikkei Stock Average Rises 1.3% to 61252.50
M impact | EQUITY | Nov 11, 2026, 04:40 AM UTC
IIFL Finance shares extend gains, up 9.4%
M impact | EQUITY | Nov 11, 2026, 04:35 AM UTC
Reliance Industries shares rise 1.2%
L impact | EQUITY | Nov 11, 2026, 04:34 AM UTC
HEG Advanced Materials Subsidiary Gets ₹609.50 Crore ECMS Incentive Approval
The company said its wholly owned subsidiary TACC received an approval letter for a ₹609.50 crore incentive under the Electronics Component Manufacturing Scheme. HEG Advanced Mater
M impact | EQUITY | Nov 11, 2026, 04:31 AM UTC
TYM Corp to Acquire 10 Billion Won of Its Own Shares
M impact | EQUITY | Nov 11, 2026, 04:31 AM UTC